KP-1461
KP-1461 is an experimental antiretroviral drug that was under development for the treatment of HIV/AIDS. It belongs to a class of drugs known as viral mutagens, which work by inducing high rates of mutation in the HIV virus, thereby causing it to self-destruct.
Mechanism of Action[edit | edit source]
KP-1461 works by inducing a process known as viral error catastrophe or lethal mutagenesis. This process involves the introduction of a high rate of mutations into the genetic material of the virus, which leads to the production of nonviable offspring and ultimately, the collapse of the viral population.
The drug is a nucleoside reverse transcriptase inhibitor (NRTI), which means it interferes with the action of reverse transcriptase, an enzyme that HIV uses to replicate its genetic material. However, unlike other NRTIs, KP-1461 is designed to increase, rather than decrease, the rate of mutation during this process.
Clinical Trials[edit | edit source]
KP-1461 has undergone Phase I and Phase II trials. The results of these trials suggested that the drug was well-tolerated and had a favorable safety profile. However, the drug did not show a significant reduction in viral load, which led to the discontinuation of its development.
Potential Advantages and Disadvantages[edit | edit source]
One of the potential advantages of KP-1461 is that it could overcome the problem of drug resistance, which is a major challenge in the treatment of HIV/AIDS. By causing the virus to self-destruct, the drug could potentially be effective against all strains of HIV, including those that have developed resistance to other antiretroviral drugs.
However, the approach of inducing lethal mutagenesis also carries potential risks. For example, there is a concern that the high rate of mutation could lead to the emergence of more virulent or drug-resistant strains of the virus. In addition, the long-term effects of such a high rate of mutation on the host's cells are unknown.
See Also[edit | edit source]
- Antiretroviral drug
- Viral mutagen
- HIV/AIDS
- Viral error catastrophe
- Nucleoside reverse transcriptase inhibitor
- Drug resistance
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
